Safety FDA Assessment

ZEVALIN™ therapy is characterized by a high incidence of cytopenias

Gr. 3-4 ANC 55%

Gr. 3-4 PLT 57%

median duration 3-4 weeks

Previous slide

Next slide

Back to first slide

View graphic version